157 related articles for article (PubMed ID: 20186752)
21. miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3.
Fan CG; Wang CM; Tian C; Wang Y; Li L; Sun WS; Li RF; Liu YG
Oncol Rep; 2011 Nov; 26(5):1281-6. PubMed ID: 21725618
[TBL] [Abstract][Full Text] [Related]
22. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development.
Shigoka M; Tsuchida A; Matsudo T; Nagakawa Y; Saito H; Suzuki Y; Aoki T; Murakami Y; Toyoda H; Kumada T; Bartenschlager R; Kato N; Ikeda M; Takashina T; Tanaka M; Suzuki R; Oikawa K; Takanashi M; Kuroda M
Pathol Int; 2010 May; 60(5):351-7. PubMed ID: 20518884
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the diagnostic and therapeutic roles of non-coding RNA and cell proliferation related gene association in hepatocellular carcinoma.
Ahmed MY; Salah MM; Kassim SK; Abdelaal A; Elayat WM; Mohamed DA; Fouly AE; Abu-Zahra FAE
Gene; 2019 Jul; 706():97-105. PubMed ID: 31034943
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-34a inhibits cell proliferation by repressing mitogen-activated protein kinase kinase 1 during megakaryocytic differentiation of K562 cells.
Ichimura A; Ruike Y; Terasawa K; Shimizu K; Tsujimoto G
Mol Pharmacol; 2010 Jun; 77(6):1016-24. PubMed ID: 20299489
[TBL] [Abstract][Full Text] [Related]
25. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.
Raver-Shapira N; Marciano E; Meiri E; Spector Y; Rosenfeld N; Moskovits N; Bentwich Z; Oren M
Mol Cell; 2007 Jun; 26(5):731-43. PubMed ID: 17540598
[TBL] [Abstract][Full Text] [Related]
26. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
Furuta M; Kozaki KI; Tanaka S; Arii S; Imoto I; Inazawa J
Carcinogenesis; 2010 May; 31(5):766-76. PubMed ID: 19843643
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of MiR-93 expression reduces cell proliferation and clonogenicity of HepG2 cells.
Xu D; He XX; Chang Y; Sun SZ; Xu CR; Lin JS
Hepatogastroenterology; 2012; 59(120):2367-73. PubMed ID: 22773266
[TBL] [Abstract][Full Text] [Related]
28. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma.
Fornari F; Gramantieri L; Ferracin M; Veronese A; Sabbioni S; Calin GA; Grazi GL; Giovannini C; Croce CM; Bolondi L; Negrini M
Oncogene; 2008 Sep; 27(43):5651-61. PubMed ID: 18521080
[TBL] [Abstract][Full Text] [Related]
29. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma.
Zhu Q; Wang Z; Hu Y; Li J; Li X; Zhou L; Huang Y
Oncol Rep; 2012 May; 27(5):1660-8. PubMed ID: 22322403
[TBL] [Abstract][Full Text] [Related]
30. Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell.
Zhou J; Wang W
J Surg Oncol; 2011 Sep; 104(3):278-83. PubMed ID: 21495032
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest.
Xu Y; Xia F; Ma L; Shan J; Shen J; Yang Z; Liu J; Cui Y; Bian X; Bie P; Qian C
Cancer Lett; 2011 Nov; 310(2):160-9. PubMed ID: 21802841
[TBL] [Abstract][Full Text] [Related]
32. [Construction and identification of the human liver-specific miR-122 expression vector].
Huang Z; Liu C
Sheng Wu Gong Cheng Xue Bao; 2009 Apr; 25(4):587-90. PubMed ID: 19637636
[TBL] [Abstract][Full Text] [Related]
33. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Milazzo M; Chieco P; Negrini M; Calin GA; Grazi GL; Pollutri D; Croce CM; Bolondi L; Gramantieri L
Cancer Res; 2010 Jun; 70(12):5184-93. PubMed ID: 20501828
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.
Yang F; Li QJ; Gong ZB; Zhou L; You N; Wang S; Li XL; Li JJ; An JZ; Wang DS; He Y; Dou KF
Technol Cancer Res Treat; 2014 Feb; 13(1):77-86. PubMed ID: 23862748
[TBL] [Abstract][Full Text] [Related]
35. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling.
Wong QW; Ching AK; Chan AW; Choy KW; To KF; Lai PB; Wong N
Clin Cancer Res; 2010 Feb; 16(3):867-75. PubMed ID: 20103675
[TBL] [Abstract][Full Text] [Related]
36. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
37. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells.
Tazawa H; Tsuchiya N; Izumiya M; Nakagama H
Proc Natl Acad Sci U S A; 2007 Sep; 104(39):15472-7. PubMed ID: 17875987
[TBL] [Abstract][Full Text] [Related]
38. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma.
Li Y; Tan W; Neo TW; Aung MO; Wasser S; Lim SG; Tan TM
Cancer Sci; 2009 Jul; 100(7):1234-42. PubMed ID: 19486339
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1.
Wong QW; Lung RW; Law PT; Lai PB; Chan KY; To KF; Wong N
Gastroenterology; 2008 Jul; 135(1):257-69. PubMed ID: 18555017
[TBL] [Abstract][Full Text] [Related]
40. [The influence of downregulation of ezrin expression by RNA interference on the growth and metastasis of hepatocellular carcinoma: experiment in vitro].
Zhang Y; Hu MY; Chen BH; Wang ZJ; Zha XL; Liu KD
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):530-5. PubMed ID: 16681881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
